Ruxolitinib vs placebo
Progression‐free survival ‐ not measured · Patients with treating MF
1 finding from 1 review
- Janus kinase‐1 and Janus kinase‐2 inhibitors for treating myelofibrosis 2015 · Cochrane Headline outcomes onlyno estimate extracted1 study · 309 participantsGRADE not reported